therapeutic drug monitoring Latest News

Biomiga Diagnostics will be presenting data on its population pharmacokinetic/Therapeutic Monitoring Device for Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), and Human chorionic gonadotropin (hCG) in personalized IVF treatment.

Biomiga Diagnostics will be presenting data on its population pharmacokinetic/Therapeutic Monitoring Device designed for Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) with application to other protein therapeutics.

Biomiga Diagnostics announces the development of lateral flow point-of-care Therapeutic Drug Monitoring (TDM) assays for Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH). These findings will be presented at the AACR 2012

Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine, today announced it is joining Astia, a global network serving women-led high growth start-ups.

Analytical Services International (ASI) at St George’s, University of London, UK, has been evaluating LoGiCal certified reference materials – a new product range from LGC Standards – for its therapeutic drug monitoring (TDM) services.

Biomiga Diagnostics will be presenting data on its population pharmacokinetic/Therapeutic Monitoring Device for Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), and Human chorionic gonadotropin (hCG) in personalized IVF treatment.

Biomiga Diagnostics will be presenting data on its population pharmacokinetic/Therapeutic Monitoring Device designed for Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) with application to other protein therapeutics.

Biomiga Diagnostics announces the development of lateral flow point-of-care Therapeutic Drug Monitoring (TDM) assays for Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH). These findings will be presented at the AACR 2012

Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine, today announced it is joining Astia, a global network serving women-led high growth start-ups.